| Autor: |
Shadid ILC; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Guchelaar HJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Weiss ST; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Mirzakhani H; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: hoomi@post.harvard.edu. |
| Jazyk: |
angličtina |
| Zdroj: |
Life sciences [Life Sci] 2024 Oct 15; Vol. 355, pp. 122942. Date of Electronic Publication: 2024 Aug 10. |
| DOI: |
10.1016/j.lfs.2024.122942 |
| Abstrakt: |
Vitamin D 3 's role in mineral homeostasis through its endocrine function, associated with the main circulating metabolite 25-hydroxyvitamin D 3 , is well characterized. However, the increasing recognition of vitamin D 3 's paracrine and autocrine functions-such as cell growth, immune function, and hormone regulation-necessitates examining vitamin D 3 levels across different tissues post-supplementation. Hence, this review explores the biodistribution of vitamin D 3 in blood and key tissues following oral supplementation in humans and animal models, highlighting the biologically active metabolite, 1,25-dihydroxyvitamin D 3 , and the primary clearance metabolite, 24,25-dihydroxyvitamin D 3 . While our findings indicate significant progress in understanding how circulating metabolite levels respond to supplementation, comprehensive insight into their tissue concentrations remains limited. The gap is particularly significant during pregnancy, a period of drastically increased vitamin D 3 needs and metabolic alterations, where data remains sparse. Within the examined dosage ranges, both human and animal studies indicate that vitamin D 3 and its metabolites are retained in tissues selectively. Notably, vitamin D 3 concentrations in tissues show greater variability in response to administered doses. In contrast, its metabolites maintain a more consistent concentration range, albeit different among tissues, reflecting their tighter regulatory mechanisms following supplementation. These observations suggest that serum 25-hydroxyvitamin D 3 levels may not adequately reflect vitamin D 3 and its metabolite concentrations in different tissues. Therefore, future research should aim to generate robust human data on the tissue distribution of vitamin D 3 and its principal metabolites post-supplementation. Relating this data to clinically appropriate exposure metrics will enhance our understanding of vitamin D 3 's cellular effects and guide refinement of clinical trial methodologies.
Competing Interests: Declaration of competing interest None.
(Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect